This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

BioCryst Broad-Spectrum Antiviral BCX4430 Highly Effective Against Yellow Fever In A Preclinical Disease Model

Stocks in this article: BCRX

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced proof-of-principle data demonstrating that BCX4430 is efficacious and well tolerated in a preclinical disease model for evaluating efficacy against yellow fever virus infection. BCX4430 is the lead compound in BioCryst’s broad-spectrum antiviral (BSAV) research program. The objective of BioCryst’s BSAV program is to develop broad-spectrum parenteral and oral therapeutics for viruses that pose a threat to national health and security.

A presentation entitled “BCX4430, an adenosine analog, with potent activity against yellow fever virus in a hamster model,” will be presented by Dr. Justin Julander at the 2nd Antivirals Congress in Cambridge, MA today at 5:10PM E.T.

These studies comprehensively evaluated the efficacious dose, dose duration, and therapeutic use of parenteral BCX4430 in the treatment of yellow fever infection. Syrian Golden Hamsters–a widely accepted model for establishing efficacy against yellow fever —virus were inoculated intraperitoneally with ten times the cell culture infectious dose (CCID 50) of yellow fever virus (Jimenez strain) and treated parenterally with BCX4430 administered either once or twice daily for 4 to 7 days. In studies with treatment just prior to infection or delayed up to 4 days after infection, BCX4430 treated animals had significantly (p<0.001) improved survival (80–100%) compared to animals receiving saline placebo (20-30%). It is important to note that in this model, serum viral titers peak at day four after infection, indicating that BCX4430 has the potential to be an effective therapeutic when administered as pre-exposure prophylaxis; as post-exposure prophylaxis during the virus incubation period; and as a treatment during the prodromal period and symptomatic disease. Treated animals also exhibited significantly lower viral titers in serum, improved weight gain, and decreased liver damage as measured by lower levels of alanine transaminase and aspartate transaminase.

In addition, BCX4430 demonstrated a wide therapeutic index of 50 with a minimum effective dose of 4 mg/kg/day (p<0.05 vs control), as measured by survival, and a maximum tolerated dose of 200 mg/kg/day, as measured by percent weight change.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,805.41 +127.51 0.76%
S&P 500 1,964.58 +13.76 0.71%
NASDAQ 4,483.7150 +30.9230 0.69%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs